Skip to main content
. 2018 Apr 27;57(18):2647–2655. doi: 10.2169/internalmedicine.0793-18

Table 1.

Demographic and Clinical Characteristics of 10 Patients with Multiple Sclerosis Who Experienced Clinical or MRI Exacerbation after Fingolimod Cessation.

Group I Group II Group III
Patient No. 1 2 3 4 5 6 7 8 9 10
Sex F F F F M F F F F F
 
At fingolimod initiation
Disease duration (years) 1 4 2 13 37 13 23 3 7 5
ARR (preceding year) 3 2 1 0 1 1 1 0 1 1
Clinical course RR RR RR SP RR SP SP mono RR RR
EDSS 6.5 1.0 2.5 6.5 2.5 4.5 4.5 0.0 1.5 0.0
 
During fingolimod therapy
Duration of fingolimod treatment (weeks) 124 264 144 260 248 202 152 120 84 144
ARR 3 0 0 0 0 0 0 0 0 0.36
EDSS 6.5 1.0 2.5 6.5 2.5 4.5 4.5 0.0 1.5 0.0
 
Age at fingolimod cessation (years) 54 37 36 46 59 44 58 34 45 39
 
Clinical or MRI exacerbation after fingolimod cessation
Time from fingolimod cessation ( days) 16 98 87 52 42 140 141 36 91 21
EDSS 7.0 1.5 3.5 7.5 2.5 4.5 4.5 0.0 1.5 2.5
 
Days from fingolimod cessation to DMF initiation 41 n.i. 134 64 43 32 84 35 36 43
 
Peripheral blood lymphocyte count (/μL)
At fingolimod cessation 530 372 103 90 497 481 326 411 479 368
4 weeks after fingolimod cessation 1,431 499 297 1,468 1,081 979 638 1,209 1,191 718

ARR: annual relapse rate, EDSS: expanded disability status scale, DMF: dimethyl fumarate, MRI: magnetic resonance imaging, RR: relapsing-remitting, SP: secondary progressive, mono: monophasic, n.i.: not induced